the stock of a company is like a piece of paper that represents the company. People buy and sell these pieces of paper, hoping that the value of the paper will go up or down depending on how well the company is doing. Sometimes, people who know a lot about a company will say how much they think the paper will be worth in the future. This is called a price target. But, just like when you guess how many candies are in a jar, sometimes people guess wrong. So, when you hear about price targets, remember that they are just people's guesses and you should not rely on them alone to make decisions about buying or selling the paper. Read from source...

in general, critics who lacked objectivity and professionalism, and whose criticisms were often unfounded, misguided, and misinformed.

In particular, the critics' main argument appeared to be based on the assumption that price targets set by analysts were always overly optimistic, inaccurate, and irrelevant. This assumption, however, was largely misguided and misleading, as it failed to acknowledge the fact that analysts' price targets were often based on sound financial reasoning, thorough research, and deep understanding of the underlying factors affecting the company's performance.

Moreover, the critics' lack of attention to the agreement among analysts about the company's earnings prospects and the correlation between trends in earnings estimate revisions and near-term stock price movements was a significant oversight that undermined the validity of their criticisms.

Overall, the critics' approach appeared to be based on a misguided and incomplete understanding of the factors influencing the stock's potential upside, which made their criticisms largely irrelevant and unhelpful.

bullish
### Explanation:
This article presents an analysis of Foghorn Therapeutics Inc. (FHTX) stock's potential for an upside, according to Wall Street analysts' short-term price targets. The mean price target of $15 indicates an 81.2% upside potential. Moreover, analysts' growing optimism over the company's earnings prospects could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Therefore, while the consensus price target may not be a reliable indicator of how much FHTX could gain, the direction of price movement it implies does appear to be a good guide.

While the stock closed at $8.28 and has seen a 35.3% gain over the past four weeks, Foghorn Therapeutics (FHTX) could see an 81.2% upside according to mean short-term price targets set by Wall Street analysts. While a positive trend in earnings estimate revisions could indicate an upside, analysts' price targets should be viewed with a degree of skepticism as they often mislead investors rather than guide them. Additionally, analysts' overly optimistic price targets are often driven by business incentives of firms covering a stock.